About Modi Ventures
Modi Ventures is a family office founded in 2022. It is primarily based out of Houston, United States. As of Jul 2026, Modi Ventures is an active investor, having invested in 14 companies, with 5 new investments in the last 12 months. It primarily invests in Series A round in United States based companies. Its investments are spread across a wide range of sectors from Life Sciences, Enterprise Applications. Its latest investment was a $83M Series A round in Cytospire Therapeutics on May 05, 2026, which also saw participation from 4Bio Capital and Servier.
Overall, Modi Ventures portfolio has seen 1 unicorn including key companies like Brainomix, RUBEDO LIFE SCIENCES and Lila Sciences. A lot of funds co-invest with Modi Ventures, with names like DCVC sharing a substantial percentage of its portfolio.
Modi Ventures has a team of 15 people including 1 partner.
Key Metrics
Founded Year
2022
Location
Houston, United States
Portfolio Companies
Sectors of Investment
Stages of Investment
Series A, Seed & 2 more
Locations of Investment
Unicorn in Portfolio
Modi Ventures' List of Top Investments
Modi Ventures has a portfolio of 14 companies, one of which is a Unicorn. Their most notable investments include Brainomix and RUBEDO LIFE SCIENCES.Their portfolio spans across United States, United Kingdom and Germany. They have invested in Life Sciences, Enterprise Applications, HealthTech and 5 other sectors, across stages such as Series A, Seed and 2 more. Here is the list of top investments by Modi Ventures:1. Brainomix
Developer of automated medical imaging software for stroke and lung. This technology processes medical scans to identify biomarkers and assist in clinical assessment. The software provides automated analysis for stroke detection and lung disease evaluation. These tools support diagnostic workflows by generating insights from imaging data to assist in treatment decisions.
Key facts about Brainomix
- Founded Year: 2010
- Location: Oxford (United Kingdom)
- Annual Revenue: £1M - £10M as on Dec 31, 2025
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $63.3M
- Employee Count: 87 as on Jun 30, 2026
- Investors: Boehringer Ingelheim Venture Fund, Tencent and 16 Others
- Latest Funding Round: Series C, Oct 24, 2025, $*****
- Highlight: Editors' Pick
Developer of therapeutics for age-related diseases. The company uses propriety technology includes the ALEMBIC that focuses on developing medicines to combat biological aging by targeting pathologic cells like senescent ones that drive age-related diseases.
Key facts about RUBEDO LIFE SCIENCES
- Founded Year: 2018
- Location: Sunnyvale (United States)
- Stage: Series A
- Total Funding till date: $52M
- Employee Count: 31 as on Jun 30, 2026
- Investors: The Longevity Fund, Ahren and 11 Others
- Latest Funding Round: Series A, Apr 22, 2024, $*****
- Highlight: Editors' Pick
Developer of AI-powered autonomous scientific research platforms. These platforms integrate AI models with autonomous laboratory systems to design, conduct, and analyze scientific experiments across life, chemical, and materials sciences. The goal is to accelerate scientific discovery and address significant challenges by significantly increasing the speed, scale, and accuracy of research beyond human capabilities alone. This approach aims to reinvent the scientific method through the application of artificial intelligence.
Key facts about Lila Sciences
4. Latus
Developer of gene therapy medicines for neurological diseases. The company leverages precision delivery through Adeno-Associated Virus to target specific cells and tissues, to improve the lives of patients suffering from various central nervous system disorders.
Key facts about Latus
- Founded Year: 2022
- Location: Philadelphia (United States)
- Stage: Series A
- Total Funding till date: $151M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: BioAdvance, DCVC and 8 Others
- Latest Funding Round: Series A, May 04, 2026, $*****
- Highlight: Editors' Pick
Developer of CAR-T cell therapies for malignancies. It offers a ead asset, MB-105 which is designed to treat relapse/refractory T-cell malignancies which include leukemia, lymphoma, and others. It also has MB-107, MB-112, and MB-301 for multiple cancers.
Key facts about March Biosciences
- Founded Year: 2022
- Location: Houston (United States)
- Stage: Series A
- Total Funding till date: $33.2M
- Employee Count: 24 as on Jun 30, 2026
- Investors: 4Bio Capital, Mission BioCapital and 11 Others
- Latest Funding Round: Grant (prize money), Jun 20, 2025, $*****
- Highlight: Editors' Pick
Modi Ventures' Year-on-Year Investment Trends
In 2025, it made 5 investments, while as of May 2026, it has made 4 investments in this year. Its most recent first time investment was in Cytospire Therapeutics and most recent follow-on round was in Latus.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 1 | 4 |
2025 | 5 | 0 | 5 |
2024 | 5 | 0 | 5 |
Modi Ventures' Investments by Stage
Modi Ventures has made 6 investments in Series A stage with an average round size of $37.5M, 5 investments in Seed stage with an average round size of $77.3M, 1 investment in Series B stage with an average round size of $59.3M and 1 investment in Series C stage with an average round size of $6.5M.Stage of entry | No. of Investments |
|---|---|
Series A | 6 |
Seed | 5 |
Series B | 1 |
Series C | 1 |
Note: We have considered here, only first round of investments
Modi Ventures' Investments by Sector
Modi Ventures has a diverse portfolio, with companies operating in the Life Sciences, HealthTech, Enterprise Applications, Artificial Intelligence - Industry Applications and Consumer. Notably, it has invested in 12 Tech companies, 11 Enterprise (B2B) companies, 7 Software companies and at least 4 companies focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 8 |
HealthTech | 7 |
Enterprise Applications | 5 |
Artificial Intelligence - Industry Applications | 3 |
Consumer | 2 |
Others | 7 |
Note: We have considered here, only first round of investments
Modi Ventures' Investments by Geography
Modi Ventures has made most investments in United States (9), followed by United Kingdom where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 9 |
United Kingdom | 3 |
Germany | 1 |
Note: We have considered here, only first round of investments
Modi Ventures' recent investments
Modi Ventures has made 4 investments in 2026 so far. Cytospire Therapeutics and Latus are the latest among them.Here are the most recent investments by Modi Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 05, 2026 | United Kingdom | Series A | 9252 | [+8] | |
May 04, 2026 | United States | Series A | 8665 | [+6] | |
Jan 20, 2026 | Germany | Series B | 9185 | [+6] | |
Jan 12, 2026 | United States | Seed | 9732 | [+7] | |
Oct 24, 2025 | United Kingdom | Series C | 3070 |
Unicorns in Modi Ventures' Portfolio
Modi Ventures has 1 unicorn in its portfolio - Lila Sciences. The most recent unicorn in their portfolio is Lila Sciences which became a unicorn in 2025.Here is a list of unicorns in Modi Ventures' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
59 | Developer of AI-powered autonomous scientific research platforms | 2023 | Cambridge | Series A | aesbcru |
Team profile of Modi Ventures
Modi Ventures has a team of 15 members including 1 Partner and 10 Venture Partners located in United States and United Kingdom. Modi Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Modi Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Sugar Land | - | - | |
Venture Partner | - | - | - | |
Venture Partner | New York | - | - | |
Venture Partner | United Kingdom | - | ||
Venture Partner | San Francisco | - | - | |
Venture Partner | Pleasanton | - | ||
Venture Partner | - | - | ||
Venture Partner | - | - | ||
Venture Partner | Danville | - | ||
Venture Partner | Miami | - | - | |
Venture Partner | Houston | - | - |
Co-investors of Modi Ventures
Over the past 2 years, 100 investors have co-invested in Modi Ventures's portfolio companies. This includes funds and angels.
- Invested before Modi Ventures: Parkwalk, Chimera Partners and 17 others have invested in rounds before Modi Ventures. There is 1 company where Parkwalk has invested before Modi Ventures and 1 company where Chimera Partners has invested before Modi Ventures.
- Top Co-investors of Modi Ventures: 68 investors entered a company along with Modi Ventures. These include investors like DCVC (2 companies).
- Invested after Modi Ventures: A total of 13 investors have invested in Modi Ventures's portfolio after their investments. Top Investors include Collective Global (1 company) and Braidwell (1 company).
Recent News related to Modi Ventures
•
Latus Bio to Present New Data at ASGCT 2026 Supporting Investigational Gene Therapy Approaches for Huntington’s Disease and CLN2 DiseaseBusiness Wire•Apr 28, 2026•Latus, Modi Ventures, Hatch BioFund, Gaingels and 4 others
•
Brainomix extends Series C round to £18.8m amid US expansionInsider Media•Feb 24, 2026•Brainomix, Modi Ventures, Hostplus, FW Capital
•
EQT Life Sciences co-leads EUR 51 million Series B in Exciva to advance Alzheimer's therapyPR Newswire•Jan 20, 2026•Modi Ventures, CARMA FUND, Exciva, Landesbank Baden Wurttemberg and 6 others
•
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based MedicinesBusiness Wire•Jan 13, 2026•Braidwell, NVentures, Modi Ventures, Magnetic Ventures and 11 others
•
US AI biotech startup Lila Sciences raises $235m, valued at $1.2bTech in Asia•Sep 15, 2025•Lila Sciences, Collective Global, Braidwell, Modi Ventures and 1 other
•
•
Lila Sciences raises $200M to accelerate autonomous scientific researchSiliconAngle•Mar 11, 2025•Lila Sciences, General Catalyst, March Capital, Ark Invest ETFs and 3 others
•
Lila Raises 200M in Committed Seed CapitalFinSMEs•Mar 10, 2025•Lila Sciences, Flagship Pioneering, General Catalyst, March Capital and 6 others
•
London MedTech raises £5.5m to address $400bn annual issueBusinessCloud•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
•
Ignota Labs Secures $6.9M to Bring ‘Dead’ Drugs Back to Life with AISynBioBeta•Feb 26, 2025•Ignota Labs, Montage Ventures, AIX Ventures, Modi Ventures and 2 others
